<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>BioScreening - organic compounds for screening</title>
<link>http://www.bioscreening.com/index/</link>
<description>Business Directories of Suppliers for Chemicals for Bioscreening and Combinatorial Chemistry, Databases for Drug Discovery, Test systems for Screening of Tubulin modulators, Custom Synthesis and other Biotech Industries</description>
<generator>BBDMS 1.0.0</generator>
<managingEditor>info@bioscreening.com (Somebody)</managingEditor>
<webMaster>info@bioscreening.com (Somebody)</webMaster>
<pubDate>Sat, 04 Sep 2010 14:58:59 -0400</pubDate>
<lastBuildDate>Sat, 04 Sep 2010 14:58:59 -0400</lastBuildDate>
<language>en</language>
<copyright>Copyright by Somebody</copyright>
<item>
<title>Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaborationa</title>
<link>http://www.bioscreening.net/2010/07/12/aquapharm-and-amri-enter-into-a-novel-marine-chemistry-collaboration/</link>
<description>
<![CDATA[ Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience and expertise from previous screening campaigns with its terrestrial natural products library, AMRI will screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target and will isolate and elucidate the structures of novel hits. Aquapharm retains all rights to compounds resulting from the collaboration. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Tue, 27 Jul 2010 09:31:00 -0400</pubDate>
</item>
<item>
<title>BioFocus and University of Bristol enter drug discovery collaboration in chronic pain</title>
<link>http://www.bioscreening.net/2010/07/20/biofocus-and-university-of-bristol-enter-drug-discovery-collaboration-in-chronic-pain/</link>
<description>
<![CDATA[ Saffron Walden and Bristol, UK; 16 July 2010 BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total contract value for BioFocus could exceed 3.3 million in research fees over two years. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Tue, 27 Jul 2010 09:30:00 -0400</pubDate>
</item>
<item>
<title>Nine U.S. Health Research Centers to Receive $255 Million</title>
<link>http://www.bioscreening.net/2010/07/22/nine-us-health-research-centers-to-receive-255-million/</link>
<description>
<![CDATA[ Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes of Health. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Tue, 27 Jul 2010 09:29:00 -0400</pubDate>
</item>
<item>
<title>TimTec launches a new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services.</title>
<link>http://www.timtec.net/news/press-releases/timtec-launches-division-of-organic-synthesis-and-medicinal-chemistry-contract-research-services.html</link>
<description>
<![CDATA[ TimTec launched a new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services. The emergence of the division is an evolutionally progression for TimTecs business development. The company has been known for its expertise in organic chemistry design and supply for drug discovery for 15 years. TimTec scientists have a proven track record of providing high quality services and showing outstanding integrity to their clients. ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Thu, 08 Jul 2010 23:46:00 -0400</pubDate>
</item>
<item>
<title>Molecular Templates and ImClone Systems Form Oncology Drug Discovery and Translation Research Collaboration</title>
<link>http://www.bioscreening.net/2010/07/08/molecular-templates-and-imclone-systems-form-oncology-drug-discovery-and-translation-research-collaboration/</link>
<description>
<![CDATA[ Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.
Under the terms of the […] ]]>
</description>
<author>info@bioscreening.com (Somebody)</author>
<pubDate>Thu, 08 Jul 2010 23:34:00 -0400</pubDate>
</item>
</channel>
</rss>
